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PAS1
HEALTH CARE UTILIZATION, COST AND MEDICATION USE
AMONG PEDIATRIC ASTHMA PATIENTS
Modi A, Iyer R, Lawrence L
University of Louisiana at Monroe, Monroe, LA, USA
Asthma is the most prevalent chronic condition in children and
is the number one cause of childhood hospitalizations. Revised
guidelines published by the National Institutes of Health in 1997
characterize asthma as a chronic, inﬂammatory disease and
propose speciﬁc recommendations for therapy with inhaled anti-
inﬂammatory medications and stress the importance of ambula-
tory care to achieve adequate control. Given the high prevalence
and current emphasis on monitoring asthma care by interven-
tion, it is important to evaluate its economic impact on the health
care system. OBJECTIVE: To estimate costs, health care utiliza-
tion and characterize medication use of pediatric asthma patients
in the post-guidelines era (1999–2001). METHODS: Data for
this study were derived from the 1999–2001 household compo-
nent of the Medical Expenditure Panel Survey. Pediatric asthma
patients (age °Ü 17yrs) were identiﬁed based on ICD-9-CM code
of 493. Total costs were computed in terms of direct medical
expenditures and indirect costs (based on school days or work
days missed by caregiver). All costs were computed in terms of
2003 US dollars. RESULTS: Average annual cost per-child for
1999, 2000, and 2001 was $512.37, $572.27, and $662.31
respectively. In 1999, hospitalization was the major cost driver
followed by ofﬁce-based-visits and prescription medications.
However, in 2000 and 2001, ofﬁce-based-visits were the major
cost drivers followed by prescription medications. Long-term
control medications were prescribed more frequently than quick
relief medications. Inhaled anti-inﬂammatory medications were
prescribed less when compared to other medications in the same
category. CONCLUSIONS: The study data show an increase in
the use and cost of ofﬁce-based-visits, medications and a decrease
in hospitalization costs. These ﬁndings suggest that there have
been improvements in care, consistent with the guidelines. Infor-
mation from this study can help track changes in treatment of
asthma and how the order of cost drivers has changed during
this time.
PAS2
IMPACT OF ANTI-INFLAMMATORY MEDICATION ON ASTHMA
COSTS IN A PEDIATRIC POPULATION
Sapra SJ1, Martin BC2, Dorfman JH3
1University of California, San Francisco, CA, USA; 2University of
Arkansas for Medical Sciences, Little Rock, AR, USA; 3University of
Georgia, Athens, GA, USA
OBJECTIVE: Anti-inﬂammatory medication may interrupt the
progression to and severity of asthma for pediatrics who suffer
from allergic rhinitis (AR) and/or atopic dermatitis (AD). The
objective of this study was to evaluate the impact of: ﬁrst 
generation anti-histamines (FGAH), second generation anti-
histamines (SGAH), and intra-nasal steroids (INS) on annual
asthma treatment costs in a cohort of AD/AR patients who
develop asthma. METHODS: Data from GA Medicaid (1995 to
2001) and MarketScan (commercial population—1998 to 2001)
were utilized. Newborn children free of any malignancies and
diagnosed with AD/AR who later developed asthma and were
eligible for at least 12 months after the ﬁrst asthma diagnosis
were included. All FGAH, SGAH and INS prescriptions from
birth until an asthma diagnosis were recorded and total direct
health care costs for subjects in the AD/AR cohort after the ﬁrst
asthma diagnosis were examined. Multivariate ordinary least
squares regression using Huber-white heteroscedasticity consis-
tent variance–covariance matrix after adjusting for sample selec-
tion was used to compare direct medical costs between groups
exposed to FGAH, SGAH or INS and groups with no exposure.
RESULTS: In total, 4277 in GA Medicaid and 353 asthma
patients in the commercial were included, of which 2906 (68%)
and 228 (64%) patients had at least one prescription for FGAH,
SGAH, and INS. Any exposure to these anti-inﬂammatory agents
were associated with a non-signiﬁcant lower mean total cost of
$66 PMPY (p-value = 0.50) and $497 PMPY (p-value = 0.45) in
the GA Medicaid and commercial populations. Total medical
costs (excluding prescriptions) and physician costs were $733 (p-
value = 0.04) and $303 PMPY (p-value = 0.05) lower for the
exposure groups in the commercial population. CONCLUSION:
Exposure to anti-inﬂammatory agents reduced medical costs
excluding prescription drugs in a commercial population;
however, medical costs were not signiﬁcantly lower in the 
Medicaid population.
PAS3
A COMPARISON OF ASTHMA MEDICATION USE IN PUBLICLY
VERSUS PRIVATELY INSURED CHILDREN WITH ASTHMA
Ungar WJ1, Kozyrskyj A2, Paterson M3, Mamdani M3, Gunraj N3,
Ahmad F4
1The Hospital for Sick Children,Toronto, ON, Canada; 2Manitoba
Centre for Health Policy, Winnipeg, MB, Canada; 3Institute for Clinical
Evaluative Sciences,Toronto, ON, Canada; 4Brogan Inc, Ottawa, ON,
Canada
OBJECTIVES: Asthma is the most common chronic disease in
childhood. To ensure optimal control, children must have access
to necessary medications, including inhaled corticosteroids for
maintenance and bronchodilators as needed. The objective was
to compare asthma medication use in publicly insured social
assistance children to privately insured children with asthma.
METHODS: Identical case deﬁnitions were used to created
public (n = 12,767) and private (n = 17,046) cohorts of asth-
matic Ontario children aged 2–14 years using 2002 aggregate
private sector claims and 1998–2001 Ontario Drug Beneﬁts
database claims. Use of bronchodilators (BD), inhaled corticos-
teroids (ICS), leukotriene antagonists (LA) and oral corticos-
teroids (OS) were compared between cohorts. RESULTS: In
contravention of guidelines, 12% of social assistance children
received BD monotherapy compared to 1% of privately insured
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children. Combined therapy of ICS + BD with or without LAs
was observed in 70% of privately insured children compared 
to 44% of social assistance children. Despite apparently better
management in the private group, OS use, indicating a severe
exacerbation, was 16% in the private compared to 12% in the
publicly insured group. While the average annual number of
claims were similar in the private and public groups (7.3 vs. 7.1),
privately insured children had more ICS claims (3.2 vs. 2.9) 
and fewer BD claims (2.9 vs. 3.9). CONCLUSIONS: Privately
insured children appeared to be better managed than social assis-
tance children. Differences in socioeconomic status and formu-
lary listings may explain observed differences. Policies governing
public and private drug plans must ensure adequate access to
necessary medications for children with asthma.
PAS4
PATTERNS OF PHARMACOTHERAPY UTILIZATION AMONG
CHILDREN AND ADOLESCENTS WITH MULTIPLE ASTHMA-
RELATED MORBID EVENTS ENROLLED IN A MEDICAID
PROGRAM
D’Souza AO, Smith M, Roy AN
West Virginia University, Morgantown, WV, USA
OBJECTIVE: To describe the asthma-related pharmacotherapy
utilization following a ﬁrst and second morbid event for asthma
among children and adolescents enrolled in Medicaid.
METHODS: Medicaid hospitalization and emergency room
(ER) claims with a primary ICD-9 CM diagnosis code for asthma
dated 2002 were extracted for recipients less than 21 years of
age. The corresponding asthma-related prescription claims also
were extracted. Recipients with at least two morbid events
(deﬁned as two consecutive ER or hospital visits at least 8 days
apart) formed the study cohort. Pharmacotherapy use for each
recipient was analyzed for up to a 30-day period following
his/her ﬁrst and second morbid event. RESULTS: A total of 214
recipients was identiﬁed as the study cohort consisting mainly 
of infants less than 6 years of age (50.0%), males (61.7%), 
and whites (82.2%). The proportion of recipients who ﬁlled a
prescription for a controller medication following the second
event was greater than the proportion following the ﬁrst event
(40.2% versus 34.1%). A greater proportion of recipients used
leukotriene modiﬁers (24.3%) and inhaled corticosteroids
(20.1%) than other controller drug classes following the ﬁrst
event, as well as following the second event (25.7% and 21.0%,
respectively). Following the ﬁrst event, 59.6% of recipients who
used a leukotriene modiﬁer continued using the same medication
after the second event, compared to only 27.9% of recipients
who used inhaled corticosteroids. With respect to demographic
groups, there was a very low proportion of recipients who were
black who used controller pharmacotherapy following the ﬁrst
(14.7%) and second event (23.5%). CONCLUSION: Although
there was an increase in the proportion of recipients who uti-
lized controller pharmacotherapy after a second morbid event,
there was a low use of these medications overall. Among demo-
graphic groups, blacks had the lowest utilization of controller
medications following morbid events.
PAS5
DRUG COST ANALYSIS OF TREATMENT FOR ASTHMA
OUTPATIENTS IN TAIWAN
Lu CH1,Tarn YH2
1National Defense Medical Center,Taipei,Taipei,Taiwan; 2Taipei City
Hospital,Taipei,Taiwan
OBJECTIVES: To investigate the trend of treatment costs 
for asthmatic outpatients in Taiwan from 1998 to 2002.
METHODS: Claimed database from Bureau of National Health
Insurance of Taiwan’s whole population were used to compute
the total treatment costs and drug related costs on asthmatic out-
patients during the year 1998 to 2002. Claims with ICD-9-CM
code of asthma were obtained and then sorted per person to cal-
culate the sum of treatment costs per person per year and the
ratio of drug costs per total treatment costs. RESULTS: The fol-
lowing present the yearly data from 1998 to 2002: 1) mean drug
costs per person per year: NT$.1286, 1486, 1873, 1940 and
2114; 2) mean of days per person per year: 26, 29, 36, 40 and
43 days; 3) total treatment costs of asthma : NT$. 4.3 billion,
2.9 billion, 2.4 billion, 2.5 billion and 2.7 billion; and 4) the
ratio of drug costs/total costs: 54.92%, 56.48%, 58.15%,
58.52% and 58.84%. CONCLUSIONS: Drug therapy for
patients with asthma play an important role in asthmatic care.
In Taiwan, the study indicated that drug costs per person per
year is growing every year. Future research will investigate the
appropriateness of these drug therapy and posible drug savings
in the future.
PAS6
IMPACT OF ASTHMA KNOWLEDGE ON HEALTH OUTCOMES
IN PEDIATRIC PATIENTS
Suksomboon N, Montakantikul P
Mahidol University, Payathai, Bangkok,Thailand
OBJECTIVE: To determine whether asthma knowledge of care-
givers could improve health outcomes in pediatric patients.
METHODS: The study design was a prospective randomized
controlled trial in asthma patients aged less than 12 years-old.
The study was carried out in asthma clinic at Queen Sirikit
National Institute of Child Health, Bangkok, Thailand between
August 2002 and March 2003. Eleven active and 11 control
patients were invited to attend a clinic. At the clinic the phar-
macists conducted interviews and asked all caregivers to answer
a questionnaire containing 18 true-false questions regarding
asthma knowledge. After completing the questionnaire, phar-
macists provided knowledge of asthma regarding treatment and
environmental care to caregivers in the intervention group.
During the study period, patients in both groups continued to
receive the usual care from their physicians. Patients and care-
givers were followed up during the next six months and the same
process was repeated. The outcome measure was the rate of hos-
pitalization in asthma patient between groups. RESULTS: At
baseline there are no signiﬁcant differences in asthma knowledge
between intervention and control group. At the end of study, the
intervention group is generally better at answering the asthma
questions correctly. The number of hospitalization in the inter-
vention group decreases from 31 to 13 (p < 0.05), whereas there
is no statistically signiﬁcant difference in the control group.
CONCLUSIONS: The present work suggests that pharmacist’s
involvement in asthma clinic has increased caregivers’ knowledge
leading to a decrease in the number of hospitalization. However,
further training is required for caregivers to optimize their role
in helping asthma patients. Further work could be carried out to
determine whether the results of this study are reﬂective of the
knowledge in adult patients.
PAS7
DIRECT AND INDIRECT COST OF ASTHMA IN AN EMPLOYER
POPULATION
Atherly A, Nurmagambetov T,Williams S
Centers for Disease Control and Prevention, Atlanta, GA, USA
OBJECTIVES: The purpose of this abstract is to examine the
direct and indirect costs associated with asthma in an employer
population. This work improves on previous studies of employer
populations with asthma by incorporating measures of the indi-
